Hakutulokset - Alona Zer

Tarkenna hakua
  1. 1
    Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis

    Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis Tekijä Rebecca M. Prince, Melanie Powis, Alona Zer, Eshetu G. Atenafu, Monika K. Krzyzanowska

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

    Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival Tekijä Anna May Suidan, Laila C. Roisman, Anna Belilovski Rozenblum, Maya Ilouze, Elizabeth Dudnik, Alona Zer, Nir Peled

    Julkaistu 2019
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer

    A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer Tekijä Daniel A. Goldstein, Noa Gordon, Michal Davidescu, Moshe Leshno, Conor Steuer, Nikita Patel, Salomon M. Stemmer, Alona Zer

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

    Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer Tekijä Yosef Landman, Oded Jacobi, Noga Kurman, Orly Yariv, Idit Peretz, Ofer Rotem, Elizabeth Dudnik, Alona Zer, Aaron M. Allen

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

    Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world da... Tekijä Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Abdominal Desmoid: Course, Severe Outcomes, and Unique Genetic Background in a Large Local Series

    Abdominal Desmoid: Course, Severe Outcomes, and Unique Genetic Background in a Large Local Series Tekijä Ophir, Gilad, Sivan, Shamai, Hana, Strul, Guy, Rosner, Nathan, Gluck, Naomi, Fliss Isakov, Joseph, Klausner, Ido, Wolf, Ofer, Merimsky, Yael, Goldberg, Zohar, Levi, Alona, Zer, Revital, Kariv

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

    Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung Tekijä Elizabeth Dudnik, Samuel A. Kareff, Mor Moskovitz, Chul Kim, Stephen V. Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

    Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor... Tekijä Alona Zer, Keyue Ding, Siow Ming Lee, Glenwood Goss, Lesley Seymour, Peter Ellis, Allan Hackshaw, Penelope A. Bradbury, Lei Han, Christopher J. O’Callaghan, Ming‐Sound Tsao, Frances A. Shepherd

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer

    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer Tekijä Smadar Laufer‐Geva, Anna Belilovski Rozenblum, Tal Twito, R Grinberg, Addie Dvir, Lior Soussan‐Gutman, Maya Ilouze, Laila C. Roisman, Elizabeth Dudnik, Alona Zer, Ofer Rotem, Richard B. Lanman, Nir Peled

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Primary cardiac sarcomas: A multi‐national retrospective review

    Primary cardiac sarcomas: A multi‐national retrospective review Tekijä Tom Wei‐Wu Chen, Herbert H. Loong, Amirrtha Srikanthan, Alona Zer, Reeta Barua, Jagdish Butany, Robert J. Cusimano, Yun‐Chieh Liang, Chin‐Hao Chang, Zaza Iakobishvili, Albiruni R. Abdul Razak, Jeremy Lewin

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors

    Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors Tekijä Oded Icht, Naama Darzi, Shai Shimony, Oded Jacobi, Daniel Reinhorn, Yosef Landman, Raz Mutai, Itamar Averbuch, Tzippy Shochat, Galia Spectre, Pia Raanani, Ofer Rotem, Elizabeth Dudnik, Nir Peled, Alona Zer, Avi Leader

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

    Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade Tekijä Michal Harel, Coren Lahav, Eyal Jacob, Nili Dahan, Itamar Sela, Yehonatan Elon, Shani Raveh Shoval, Galit Yahalom, Iris Kamer, Alona Zer, Ofer Sharon, David P. Carbone, Adam P. Dicker, Jair Bar, Yuval Shaked

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

    Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer Tekijä Amir Massarweh, Noa Eliakim‐Raz, Amos Stemmer, Adva Levy‐Barda, Shlomit Yust‐Katz, Alona Zer, Alexandra Benouaich‐Amiel, Haim Ben‐Zvi, Neta Moskovits, Baruch Brenner, Jihad Bishara, Dafna Yahav, Boaz Tadmor, Tal Zaks, Salomon M. Stemmer

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

    BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors Tekijä Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, S. Keren, Noa Popovits‐Hadari, Damien Urban, Moshe Mishaeli, Alona Zer, Aaron M. Allen, Natalie Maimon Rabinovich, Ofer Rotem, Teodor Kuznetsov, Tzippy Shochat, Laila C. Roisman, Jair Bar

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer

    Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer Tekijä Alona Zer, Gregory R. Pond, Albiruni R. Abdul Razak, Kattleya Tirona, Hui Gan, Eric X. Chen, Brian O’Sullivan, John Waldron, David P. Goldstein, Ilan Weinreb, Andrew Hope, John J. Kim, Kelvin Chan, Andrew K. Chan, Lillian L. Siu, Lori J. Bernstein

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

    IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as firs... Tekijä Federico Cappuzzo, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steve McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, A. Sadiq, Venice Archer, Tania Ochi Lohmann, L. Wang, Marcin Kowanetz, Wei‐Hsin Lin, A. Sandler, Howard West

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

    NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC Tekijä Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Martín, Nobuyuki Yamamoto, Ying Cheng, Vladimir Moiseyenko, Yvonne Summers, Ihor Vynnychenko, Sung Yong Lee, Maciej Bryl, Alona Zer, Mustafa Erman, Constanta Timcheva, Rajiv Raja, Kirsha Naicker, Urban Scheuring, Jill Walker, Helen Mann, Vikram K. Chand, Tony Mok

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

    Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies Tekijä Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín, Jan H.M. Schellens, Steven Kao, Wilson H. Miller, Jean‐Pierre Delord, Bo Gao, David Planchard, Maya Gottfried, Alona Zer, Shadia I. Jalal, Nicolas Penel, Janice M. Mehnert, Ignacio Matos, Jaafar Bennouna, Dong‐Wan Kim, Lei Xu, Suba Krishnan, Kevin Norwood, Patrick A. Ott

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) Tekijä Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Pravin Patel, Hadas Gantz-Sorotsky, Alona Zer, Mor Moskovitz, Giulio Metro, Yakir Rottenberg, Antonio Calles, Maximilian J. Hochmair, Kristof Cuppens, Lynn Decoster, Martin Reck, Dror Limon, Estelamari Rodríguez, Christoforos Astaras, Adrienne Bettini, Simon Häfliger, Alfredo Addeo

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

    Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program Tekijä Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael A. Schumacher, Elizabeth Dudnik, Michael Studnicka, R. Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Čufer, Hadas Sorotsky, Sayed M.S. Hashemi, Katja Mohorčič, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: